#3 Best: Biogen Idec, +73.7%
Biotechnology firm Biogen Idec (NASDAQ:BIIB) makes several high-profile therapies, including Avonex and Tysabri, which are used for the treatment of relapsing multiple sclerosis, and Rituxan for treating non-Hodgkin’s lymphoma. Shares of the biotech winner are up 73.7% in 2011, and that’s proved to be potent fiscal therapy for shareholders.

















Comments are currently unavailable. Please check back soon.